What is AbCellera Biologics Inc.'s D&A?

AbCellera Biologics Inc. (ABCL) reported D&A of $5.92M in Q1 2026.

How has AbCellera Biologics Inc.'s D&A changed year-over-year?

AbCellera Biologics Inc.'s D&A increased by 34.2% year-over-year, from $4.41M to $5.92M.

What is the long-term trend for AbCellera Biologics Inc.'s D&A?

Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s D&A has grown at a 42.3% compound annual growth rate (CAGR), from $4.48M to $18.39M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

AbCellera Biologics Inc. ABCL D&A

D&A at other companies

Twist Bioscience CorporationTWST

$6.41M+0.2%

Recursion Pharmaceuticals, Inc.RXRX

$19.67M+1.8%

AnaptysBio, Inc.ANAB

$130K-11.0%

PrecigenPGEN

$1.1M+74.7%

ZymeworksZYME

$963K-1.8%

ADMA BiologicsADMA

$1.8M-5.3%

Other financials

Income statement

See full

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

See full

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

See full

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

See full

Market cap$1.72B+59.2%

Enterprise value$1.76B+100.0%

P/S21.7×-25.0×

Profitability

See full

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Returns & leverage

See full

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbCellera Biologics Inc.'s D&A?: AbCellera Biologics Inc. (ABCL) reported D&A of $5.92M in Q1 2026.
How has AbCellera Biologics Inc.'s D&A changed year-over-year?: AbCellera Biologics Inc.'s D&A increased by 34.2% year-over-year, from $4.41M to $5.92M.
What is the long-term trend for AbCellera Biologics Inc.'s D&A?: Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s D&A has grown at a 42.3% compound annual growth rate (CAGR), from $4.48M to $18.39M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.